Learn

Why invest in the Musk universe?

Institutional-grade research, essays and video briefings on the companies shaping the next 30 years.

Featured briefing

The 2030 Musk-Universe outlook: five bets, one thesis.

A 22-minute video breakdown of the compounding effects between Tesla, SpaceX, xAI, Neuralink and X.

Briefing · 22:14 · SpaceX / Starship
Watch on YouTube

Bet 1 — Tesla energy inflection. Megapack backlog compounds at 60% CAGR. Storage becomes the highest-margin Tesla line by 2027.

Bet 2 — Starship reusability. Full stack reuse drops $/kg to LEO below $200, unlocking constellation, cargo and lunar economics simultaneously.

Bet 3 — xAI enterprise. Grok Enterprise closes the gap with OpenAI on price and X-native distribution; ARR crosses $2B by end of 2027.

Bet 4 — Optimus deployment. First 10k units land in Tesla factories; unit cost curve mirrors Model Y's 2018–2021 trajectory.

Bet 5 — X payments. Everything-app monetization reaches $8/user/year; the network becomes a distribution surface for every other Musk product.

The MuskVentures Weekly

Every Sunday: earnings, filings, launches and Musk-driven market moves — distilled by our research team.

Free. Unsubscribe anytime.

Latest research

Tap any article to expand the full briefing.

How Tesla's cash generation compounds into a multi-planetary R&D machine spanning Starship, Optimus and xAI.

9 min read
The cash engine

Tesla generates $12–15B of operating cash flow annually. That capital is Musk's strategic reserve: it de-risks capital raises at SpaceX, seeds xAI compute buys, and underwrites Optimus tooling long before any of those businesses can self-fund.

Compounding IP

Every dollar Tesla spends on FSD advances xAI's world-model stack; every Dojo wafer produced improves Optimus training throughput. The flywheel is not financial only — it is a shared substrate of chips, data and manufacturing know-how.

Where Mars fits

Starship's iterative flight campaign is the single largest R&D program in aerospace history. Tesla's operating leverage lets SpaceX prioritize cadence over margin, collapsing the cost-per-ton to LEO by an order of magnitude within the decade.

Key takeaways
  • Tesla equity is effectively a call option on the entire Musk R&D stack.
  • SpaceX cadence is downstream of Tesla's balance-sheet health.
  • The flywheel breaks if EV gross margin compresses below ~15% for multiple quarters.

A practical guide to secondary rounds, lockups and how retail can access SpaceX exposure today.

6 min read
How tenders work

Roughly every six months SpaceX runs an employee tender at a company-set clearing price. Outside capital participates through SPVs run by wealth platforms, typically with $10k–100k minimums and 1–2% management fees.

Lockups & liquidity

Secondary shares carry ROFR restrictions and can be held indefinitely. Assume 5–7 years to any liquidity event; do not size positions you may need to unwind.

Retail-accessible routes

Regulated feeder funds (Destiny, ARK Venture, Fundrise Innovation) offer sub-$500 entry with the tradeoff of platform fees and NAV lag versus direct SPV pricing.

Key takeaways
  • Tender pricing is the closest thing to a public mark — track it quarterly.
  • Fees stack: SPV + platform + carry can absorb 20–30% of upside.
  • Never exceed 5% of net worth in a single illiquid line.

Why xAI's 200k-GPU supercluster changes the economics of frontier model training — and who benefits.

12 min read
Colossus at scale

Memphis brings 200,000 H100-class GPUs online in a single fabric — larger than any published competitor cluster. Training runs that took months now complete in weeks, compressing the model release cycle.

Second-order beneficiaries

NVIDIA obviously wins the silicon leg, but the real leverage is in power infrastructure (GE Vernova, Vertiv), interconnect (Arista, Coherent) and cooling (nVent). Musk's build-fast doctrine pulls forward capex across the entire stack.

What Grok unlocks

Direct integration with X's real-time firehose gives Grok a data moat no other frontier lab can replicate — and it feeds Tesla's FSD and Optimus training loops through shared infrastructure.

Key takeaways
  • Compute is the new oil; xAI now controls a top-3 reserve.
  • Pick-and-shovel plays (power, cooling, optics) offer lower-variance exposure.
  • Watch the next tender round for xAI valuation re-rating.

Reading the tea leaves on FDA milestones, patient outcomes and the path to a $100B market.

7 min read
Where the trial stands

PRIME is enrolling paralyzed patients for the N1 implant. Early readouts show sustained BCI control of computer interfaces months post-op — a milestone no competitor has published.

Regulatory path

FDA breakthrough designation compresses review timelines but does not lower the safety bar. Expect a 2027–2028 window for a first commercial indication (spinal cord injury), followed by broader neurological expansion.

Market sizing

Bear case: BCI stays a niche assistive device — $5B TAM by 2035. Bull case: cognitive augmentation reaches the consumer edge — $100B+, but decades out.

Key takeaways
  • Neuralink is a decade-plus hold; do not underwrite for near-term liquidity.
  • Track patient count and revocation events as the single best signal.
  • Competitive threat: Synchron's endovascular approach avoids skull surgery.

Modeling the unit economics of Tesla's Cybercab fleet — capex, utilization, and take-rate.

10 min read
Unit economics

At a $30k build cost, 60% fleet utilization and $0.35/mile pricing, a single Cybercab generates ~$25k in annual gross revenue. Payback lands inside 18 months even before Tesla's platform take-rate.

The utilization question

The bull case rests on 60%+ utilization — a number ridesharing has never sustained. Charging downtime, geofencing gaps and demand troughs can drop realized utilization to 35–40%.

Regulatory drag

State-by-state approval is the gating factor. Texas and California will lead; the northeast trails by 3–5 years. Model penetration accordingly.

Key takeaways
  • Robotaxi is a step-function outcome, not a smooth ramp.
  • Watch FSD miles-per-intervention as the leading indicator.
  • The competitive set is Waymo, not Uber.

How continuous tunneling collapses the cost curve of urban transit and utility networks.

5 min read
Continuous mining

Prufrock tunnels while installing segment liners in one pass, eliminating the stop-start pattern that dominates conventional TBM cost curves. Target: $10M/mile versus $500M–1B/mile for legacy subway builds.

Where it wins first

Utility corridors and campus loops — projects where regulatory complexity is low and repeat customers (data centers, airports) exist. Vegas Loop is the reference deployment.

The scaling risk

Municipal permitting and union labor economics have historically defeated infra cost innovation. Boring's edge only compounds if it can bypass legacy procurement.

Key takeaways
  • TBM efficiency is the moat, not the tunnel product itself.
  • Boring is illiquid and small — treat as a lottery-ticket allocation.
  • Data-center power routing may be the surprise upside case.

Ready to put research into action?

Browse the marketplace and start researching assets across the Musk universe.

Explore assets